Original Data

Rev Diabet Stud, 2008, 5(2):95-101 DOI 10.1900/RDS.2008.5.95

Comparison of Metformin and Insulin in the Treatment of Gestational Diabetes: A Retrospective, Case-Control Study

Kristiina Tertti1, Ulla Ekblad1, Tero Vahlberg2, Tapani Rönnemaa3

1Department of Obstetrics and Gynecology, Turku University Central Hospital, Turku, Finland
2Department of Biostatistics, University of Turku, Turku, Finland
3Department of Internal Medicine, Turku University Central Hospital, Turku, Finland
Address correspondence to: Kristiina Tertti, e-mail: kristiina.tertti@tyks.fi

Manuscript submitted June 23, 2008; resubmitted August 23, 2008; accepted August 25, 2008.

Keywords: gestational diabetes, insulin, metformin, OGTT, birth weight, hypoglycemia


OBJECTIVES: Limited data are available on metformin therapy in gestational diabetes. The aim of the study was to compare maternal and neonatal outcomes in patients with gestational diabetes mellitus (GDM) treated with metformin with those treated with insulin, or diet alone. STUDY DESIGN AND METHODS: We conducted a retrospective study that included 45 GDM women treated with metformin, 45 women treated with insulin and 83 women with no pharmacological treatment. Subjects were matched for pre-pregnancy body mass index (BMI) and age. RESULTS: There were no differences between the metformin-treated group and the other two groups in terms of maternal outcomes (total weight gain during pregnancy or after the diagnosis of GDM, pre-pregnancy hypertension, pregnancy induced hypertension, pre-eclampsia etc.). In the diagnostic 2-hour oral glucose tolerance test, glucose values were slightly, but significantly, higher in the insulin group than in the metformin group (p < 0.003). Eighteen percent of mothers treated with metformin needed supplementary insulin therapy. No differences between the metformin-treated group and the other two groups (insulin, diet only) were observed in relation to mean birth weights, prevalence of macrosomia, or gestational weeks at delivery. The incidence of neonatal hypoglycemia was higher in the insulin group than in the metformin group (p = 0.03). There were no differences between the groups in other neonatal outcomes (small for gestational age, Apgar scores, umbilical artery pH or base excess, etc.). CONCLUSION: These retrospective data suggest that metformin is effective in controlling gestational diabetes and is not associated with a higher risk of maternal or neonatal complications compared with insulin.

Fulltext: HTML , PDF (291KB)

This article has been cited by other articles:

Metformin for gestational diabetes in routine clinical practice

Goh JE, Sadler L, Rowan J

Diabet Med 2011. In press

Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study

Ijäs H, Vääräsmäki M, Morin-Papunen L, Keravuo R, Ebeling T, Saarela T, Raudaskoski T

BJOG 2010. In press

Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee

Waugh N, Royle P, Clar C, Henderson R, Cummins E, Hadden D, Lindsay R, Pearson D

Health Technol Assess 2010. 14(45):1-183

Role of Metformin in the Treatment of Gestational Diabetes

Wensel TM

Ann Pharmacother 2009. 43(5):939-943

The management of gestational diabetes

Cheung NW

Vasc Health Risk Manag 2009. 5(1):153-164

Gestational diabetes: pathogenesis and consequences to mother and offspring

Kaaja R, Rönnemaa T

Rev Diabet Stud 2008. 5(4):194-202